Registry for prostate cancer outcomes and genetic mutations
Official title: PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Run by Prostate Cancer Clinical Trials Consortium · NCT04995198 · Data updated 2026-11-12
This study is trying to collect information from prostate cancer patients with specific genetic changes to see how these changes affect their health and to offer them genetic counseling.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 500 (estimated) |
| Sponsor | Prostate Cancer Clinical Trials Consortium Academic / other |
| Locations | 3 sites (Baltimore, Maryland and 2 other locations) |
| Status | Recruiting |
| Started | May 3, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2037 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT04995198 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men diagnosed with prostate cancer at any stage who can provide the necessary information for participation.
✕Probably not a fit
Patients who are unable or unwilling to provide the required information or do not meet the inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The PROMISE Registry aims to establish a nationwide database of prostate cancer patients who have germline pathogenic variants. It will prospectively screen around 5,000 individuals diagnosed with prostate cancer through various methods, including tissue biopsy and PSA levels. Participants will provide saliva samples for genetic testing and complete a demographic survey regarding their health and family history. If a pathogenic variant is identified, they will receive genetic counseling to discuss the implications of the results.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of genetic factors in prostate cancer, leading to improved treatment strategies and patient outcomes.
How similar studies have gone: Other studies focusing on genetic factors in cancer have shown promise, indicating that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have prostate cancer (any stage of disease or survivorship) diagnosed or documented through one of the following: * tissue biopsy, and/or * PSA greater than 100 ng/dL (1ng/ml), and/or * clear radiographic evidence of disease * Live in the United States (including Puerto Rico, Guam, American Samoa, US Virgin Islands, Northern Mariana Islands) Exclusion Criteria: * Unable or unwilling to provide all of the necessary information for eligibility * Incomplete inclusion criteria
Where it's running
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting -
University of Washington Medical Center
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Heather Cheng, MD, PhD — Fred Hutchinson Cancer Center
- Study coordinator: Jacob Vinson
- Email: pcctcpromise@mskcc.org
- Phone: 646-449-3363
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.